Many common mutations of ccRCC have been documented, such as the inactivation of the VHL gene; specific tumor immune microenvironment characteristics, such as proliferative CD4+ T cells; and ccRCC-specific CD45+ lymphoid and myeloid cells [11,12,13,14,15]. The gene discussed is PTPRC; the disease is nonpapillary renal cell carcinoma.